A Randomized, Open-label, Parallel, Phase 2a Study to Determine the Tolerability, Pharmacokinetics, and Efficacy of APD371 in Subjects With Crohn's Disease Experiencing Abdominal Pain
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Aug 2018
At a glance
- Drugs Olorinab (Primary)
- Indications Abdominal pain
- Focus Adverse reactions
- Sponsors Arena Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 06 Aug 2018 According to an an Arena Pharmaceuticals media release, data from this trial is expected in late September 2018.
- 06 Aug 2018 Status changed from recruiting to active, no longer recruiting in Jun 2018, according to an an Arena Pharmaceuticals media release.